G1 Therapeutics, Inc. (GTHX)
NASDAQ: GTHX · IEX Real-Time Price · USD
3.910
-0.040 (-1.01%)
Jul 26, 2024, 4:00 PM EDT - Market closed
G1 Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year Ending | TTM | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
| Revenue | 84.04 | 82.51 | 51.3 | 31.48 | 45.29 | - | Upgrade
|
| Revenue Growth (YoY) | 46.55% | 60.84% | 62.98% | -30.49% | - | - | Upgrade
|
| Cost of Revenue | 6.82 | 7.2 | 3.75 | 2.02 | - | - | Upgrade
|
| Gross Profit | 77.23 | 75.32 | 47.55 | 29.46 | 45.29 | - | Upgrade
|
| Selling, General & Admin | 65.14 | 71.76 | 101.03 | 96.49 | 69.45 | 40.65 | Upgrade
|
| Research & Development | 34.92 | 43.08 | 82.7 | 75.43 | 72.32 | 88.39 | Upgrade
|
| Operating Expenses | 100.06 | 114.84 | 183.73 | 171.92 | 141.76 | 129.04 | Upgrade
|
| Operating Income | -22.83 | -39.53 | -136.18 | -142.46 | -96.48 | -129.04 | Upgrade
|
| Interest Expense | -8.93 | -10.04 | -10.43 | -4.67 | -1.78 | - | Upgrade
|
| Interest & Investment Income | 2.04 | 2.47 | 0.75 | 0.04 | 0.95 | 6.58 | Upgrade
|
| Other Non Operating Income (Expenses) | 2.24 | 2.24 | 0 | -0.35 | -0.22 | 0.02 | Upgrade
|
| EBT Excluding Unusual Items | -27.48 | -44.85 | -145.86 | -147.43 | -97.52 | -122.45 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | -0.32 | - | Upgrade
|
| Pretax Income | -27.48 | -44.85 | -145.86 | -147.43 | -97.84 | -122.45 | Upgrade
|
| Income Tax Expense | 3.12 | 3.12 | 1.7 | 0.93 | 1.41 | - | Upgrade
|
| Net Income | -30.59 | -47.97 | -147.56 | -148.35 | -99.25 | -122.45 | Upgrade
|
| Net Income to Common | -30.59 | -47.97 | -147.56 | -148.35 | -99.25 | -122.45 | Upgrade
|
| Shares Outstanding (Basic) | 52 | 52 | 44 | 42 | 38 | 37 | Upgrade
|
| Shares Outstanding (Diluted) | 52 | 52 | 44 | 42 | 38 | 37 | Upgrade
|
| Shares Change (YoY) | 13.08% | 18.58% | 4.01% | 10.73% | 1.01% | 12.55% | Upgrade
|
| EPS (Basic) | -0.59 | -0.93 | -3.38 | -3.54 | -2.62 | -3.27 | Upgrade
|
| EPS (Diluted) | -0.59 | -0.93 | -3.38 | -3.54 | -2.62 | -3.27 | Upgrade
|
| Free Cash Flow | -18.18 | -38.34 | -129.13 | -132.11 | -83.74 | -102.29 | Upgrade
|
| Free Cash Flow Per Share | -0.35 | -0.74 | -2.96 | -3.15 | -2.21 | -2.73 | Upgrade
|
| Gross Margin | 91.89% | 91.28% | 92.69% | 93.60% | 100.00% | - | Upgrade
|
| Operating Margin | -27.16% | -47.91% | -265.45% | -452.59% | -213.04% | - | Upgrade
|
| Profit Margin | -36.40% | -58.13% | -287.63% | - | -219.18% | - | Upgrade
|
| Free Cash Flow Margin | -21.63% | -46.46% | -251.70% | -419.71% | -184.92% | - | Upgrade
|
| EBITDA | -22.33 | -39.01 | -135.65 | -141.99 | -95.89 | -128.69 | Upgrade
|
| EBITDA Margin | -26.57% | -47.28% | -264.42% | - | -211.76% | - | Upgrade
|
| D&A For EBITDA | 0.5 | 0.51 | 0.53 | 0.47 | 0.58 | 0.36 | Upgrade
|
| EBIT | -22.83 | -39.53 | -136.18 | -142.46 | -96.48 | -129.04 | Upgrade
|
| EBIT Margin | -27.16% | -47.91% | -265.45% | - | -213.04% | - | Upgrade
|
| Revenue as Reported | 84.04 | 82.51 | 51.3 | 31.48 | 45.29 | - | Upgrade
|
Source: S&P Capital IQ. Standard template.